var text = [{"boxId":"1","infoText":"Management of antiplatelet therapy in patients with lower extremity artery disease <em>not</em> requiring anticoagulation<sup>a<\/sup>","boxType":BoxTypes.ACTIVITY_STARTING_POINT,"nextBox":"2"},{"boxId":"2","infoText":"Which of the following is applicable?","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"Asymp­toma­tic","eventAction":"3"},{"text":"Symp­toma­tic","eventAction":"4"},{"text":"Revasc­ulari­zation","eventAction":"5"}]},{"boxId":"3","infoText":"No SAPT<sup>b <\/sup><sup> <\/sup>(<em>Class III A</em>)","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"4","infoText":"SAPT<sup>c, e <\/sup>(A or C) (<em>Class I A)</em>","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"5","infoText":"Percutaneous or surgery?","boxType":BoxTypes.DECISION_GOING_THROUGH,"buttons":[{"text":"Percutaneous","eventAction":"6"},{"text":"Surgery","eventAction":"7"}]},{"boxId":"6","infoText":"<ul>\n<li>DAPT (A + C) for upto 1 month (<em>Class IIa C</em>)<\/li>\n<li>SAPT<sup>c, e <\/sup>(A or C) (<em>Class IIa C</em>)<\/li>\n<\/ul>","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"7","infoText":"<ul>\n<li>SAPT<sup>c, e<\/sup> (A or C) <sup> <\/sup>(<em>Class IIb B</em>)<\/li>\n<li>VKA<sup>c, e<\/sup> (O) <em>(Class</em> IIb B)<\/li>\n<\/ul>","boxType":BoxTypes.ACTIVITY_EXIT_BOX},{"boxId":"998","boxType":BoxTypes.FOOTER,"hasFootnote":true,"referenceText":"<sup>a<\/sup>e.g. concomitant AF or mechanical valve prosthesis.<br><sup>b<\/sup>SAPT should be considered if there is another concomitant atherosclerotic disease (e.g. coronary artery disease).<br><sup>c<\/sup>DAPT may be considered in patients with recent acute coronary syndrome and\/or percutaneous coronaryintervention (&lt;1 year), stenting of the last patent coronary artery, multiple coronary vessel disease in diabetic patients with incomplete revascularization.<br><sup>d<\/sup>Evidence is weak and bleeding doubles as compared to SAPT.<br><sup>e<\/sup>Stands for as long as it is well tolerated.","hasAbbreviation":true,"abbreviationText":"A = Aspirin 75–100 mg\/day; C = Clopidogrel 75 mg\/day; O = Oral Anticoagulation; DAPT = dual antiplatelet therapy; SAPT = single antiplatelet therapy; VKA = vitamin K antagonist","staticImageName":"interactive_0001436","extraButtons":[{"buttonRow":[{"text":"Abbreviation(s) and Footnote(s)","buttonId":FooterButtons.REF_BUTTON},{"image":"Flip PDF","buttonId":FooterButtons.PDF_BUTTON}]},{"buttonRow":[{"text":"Reset","buttonId":FooterButtons.RESET_BUTTON},{"text":"<a class='more-info-link' href='ref_ENAS5327_6.3.0.0.html'>More Information</a>","buttonId":FooterButtons.MORE_INFO_BUTTON}]}]}];